MilliporeSigma this week announced an investment of $110 million to construct a second commercial facility in Carlsbad, California. The manufacturing facility, to encompass 140,000 sq. ft., will expand the company’s BioReliance® viral and gene therapy service offering. Plans for the site include support for viral and gene therapy production at the 1000-liter scale using MilliporeSigma’s Mobius® single-use equipment and the addition of 11 suites capable of supporting various steps in the manufacturing process. These are expected to include viral bulk manufacturing cleanroom suites and fill/finish suites. Learn More